Tenderwize
Back to tender search

Non-exclusive agreement for fremanezumab medicines

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Mar 31, 2028 · 540 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Fremanezumab (ATC-Code: N02CD03) im Wege eines Open-House-Modells

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

52 / 100

Complexity

58 / 100

Risk factors

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Mar 31, 2028

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing the active substance fremanezumab (ATC code N02CD03).
  • Open-House participation model for non-exclusive contractual arrangements.
Show full summary

This is an Open-House supply arrangement for pharmaceutical products containing fremanezumab (ATC N02CD03), led by AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet and accept the participation conditions. No individual negotiations or guaranteed minimum purchase volumes are provided. Participation documents must be obtained via DTVP after access approval, and participation requests are submitted electronically through the portal communication function. The arrangement runs until 31 March 2028 at the latest. The notice contains several technical/formal fields that are stated to have no substantive legal meaning for this Open-House procedure.

Risks

The exact submission instructions and all deadlines are said to be contained in project-room documents that were not pr...

Only pharmaceutical undertakings within the meaning of section 4(18) AMG may participate, and local representatives qua...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of the notice.

Eligibility

  • The declaration on non-existence of exclusion grounds must be completed and submitted.

Administrative

  • Participation conditions in the documents must be accepted.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive agreement for fremanezumab medicines

Open-House supply arrangement for medicines containing fremanezumab (ATC N02CD03). The lot is described as a non-exclusive agreement open to all interested pharmaceutical companies that satisfy the participation conditions. No minimum purchase quantity is guaranteed and demand is stated to be unknown. Place of performance is Dresden, Germany, with broader reference to Germany / Saxony / Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Mar 2026 - Mar 2028

Category

Pharmaceutical products

Deadline

Deadline Mar 31, 2028

Procurement Details

Publication date
05 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
88189-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30